Press "Enter" to skip to content

Non-Small Cell Lung Cancer Market: Overview, Historical and Forecast Epidemiology Analysis, Pipeline, and Forecast 2017-30

DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) – Market Insights, Epidemiology and Market Forecast – 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells.

NSCLC is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas and sarcomatoid carcinomas.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Non-Small Cell Lung Cancer Epidemiology

The Non-Small Cell Lung Cancer epidemiology division provides the insights about historical and current Non-Small Cell Lung Cancer patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.

Non-Small Cell Lung Cancer Market
Non-Small Cell Lung Cancer Market

Non-Small Cell Lung Cancer Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030 segmented into:

  • Total Incident cases of NSCLC patients,
  • Total Incident cases of NSCLC patients by Histology,
  • Total Diagnosed cases of NSCLC patients by Stages,
  • Total NSCLC cases of patients by Genetic mutation/Biomarkers, and
  • Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC

Visit to know more.

Non-Small Cell Lung Cancer Treatment Scenario  

There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include: Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.

Request for sample pages

Non-Small Cell Lung Cancer Approved Drugs

  • Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)
  • Imfinzi (Durvalumab): AstraZeneca
  • Opdivo (Nivolumab): Bristol-Myers Squibb
  • Tecentriq (Atezolizumab): Hoffmann-La Roche
  • Keytruda (Pembrolizumab): Merck
  • Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib): Novartis
  • Tagrisso (Osimertinib): AstraZeneca
  • Lorbrena/Lorviqua (Lorlatinib): Pfizer
  • Vizimpro (Dacomitinib): Pfizer, and others.

Non-Small Cell Lung Cancer Market Outlook

There are several treatment options available to treat this condition in the seven major markets. Typically, chemotherapy, targeted treatments, and immunotherapy—alone or in combination—are used to treat lung cancer. Besides, pharmacological treatment choices, surgery, and radiation are also frequently opted. When the patient is in the initial stages, the tumor is usually resectable. Most stage I and stage II NSCLC are treated with surgery to remove the tumor.

According to DelveInsight, Non-Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017–2030. The total therapeutic market of Non-Small Cell Lung Cancer in seven major markets was found to be USD 9,730 million in 2017 which is expected to increase during the study period (2017–2030).

Non-Small Cell Lung Cancer Emerging Drugs

  • Nazartinib/EGF816: Novartis Pharmaceuticals
  • Capmatinib/INC280: Novartis Pharmaceuticals
  • Telisotuzumab Vedotin: AbbVie
  • JNJ-61186372/JNJ-6372: Janssen Pharmaceuticals
  • Ensartinib/X-396: Xcovery
  • Selpercatinib (LY3527723/LOXO-292): Eli Lilly and Company
  • SAR408701: Sanofi
  • Braftovi/encorafinib + Mektovi/binimetinib: Pfizer, and others.

Scope of the Report

  • The report covers the descriptive overview of Non-Small Cell Lung Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Non-Small Cell Lung Cancer epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Non-Small Cell Lung Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Non-Small Cell Lung Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Non-Small Cell Lung Cancer market

Table of contents

  1. Key Insights
  2. Executive Summary of NSCLC
  3. SWOT Analysis of NSCLC
  4. NSCLC: Market Overview at a Glance
  5. Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
  6. Diagnosis of NSCLC
  7. Epidemiology and Patient Population
  8. EU-5 Epidemiology
  9. Japan Epidemiology
  10. Guideline of NSCLC
  11. Unmet Needs of NSCLC
  12. Key Endpoints in NSCLC Clinical Trials
  13. Marketed Therapies
  14. Emerging Therapies
  15. Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
  16. PD-L1—Market Size
  17. BRAF Mutation—Market Size
  18. c-MET Mutation—Market Size
  19. EGFR Mutation—Market Size
  20. ALK-Mutation—Market Size
  21. Market Access and Reimbursement of NSCLC Therapies
  22. Market Drivers of NSCLC
  23. Market Barriers of NSCLC
  24. Appendix
  25. DelveInsight Capabilities
  26. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 


About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Browse through our vast repository from here.